The 2025 International Xenotransplantation Association (IXA) Congress in Geneva, convened in parallel with World Health Organization meetings on xenotransplantation guidance, marked a transition in clinical xenotransplantation from demonstrating that pig organs can function in humans to defining how graft injury is detected, interpreted, and managed in real time. We synthesize the major clinical themes that emerged from the meeting across kidney, heart, liver, and lung xenotransplantation. In kidney xenotransplantation, the NYU and Massachusetts General Hospital living‐recipient experiences now delineate two complementary injury patterns—antibody‐ and complement‐driven with a membranoproliferative, IgA‐positive, innate‐rich phenotype, and T cell–mediated with persistent innate immune activation—both converging on macrophage and NK‐cell biology that conventional immunosuppression does not address. The first registration‐supporting Phase 1/2/3 trial of a 10‐gene‐edited xenokidney (EXPAND) has begun, framed by IXA position‐paper recommendations and supported by recent FDA approvals. In cardiac xenotransplantation, real‐time complement‐function monitoring, global longitudinal strain, and donor‐derived cell‐free DNA emerge as an actionable surveillance toolkit, while other allotransplant biomarkers translate poorly. In liver xenotransplantation, extracorporeal cross‐circulation and the first preliminary data describing auxiliary pig‐to‐human liver transplant (171‐day survival) position porcine livers as bridge‐support platforms rather than definitive replacements. Lung xenotransplantation remains confined to ex vivo perfusion and short‐term preclinical models. Cross‐cutting priorities include donor‐pig design and individual graft phenotyping that accounts for transgene expression heterogeneity, prospectively validated multimodal monitoring, management of nephrotic‐range proteinuria and associated urinary loss of biologic immunosuppressants, and dedicated registry, ethical, and patient‐engagement infrastructure to support trustworthy clinical expansion.